These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 31834357)

  • 1. The cardiac sympathetic co-transmitter neuropeptide Y is pro-arrhythmic following ST-elevation myocardial infarction despite beta-blockade.
    Kalla M; Hao G; Tapoulal N; Tomek J; Liu K; Woodward L; ; Dall'Armellina E; Banning AP; Choudhury RP; Neubauer S; Kharbanda RK; Channon KM; Ajijola OA; Shivkumar K; Paterson DJ; Herring N
    Eur Heart J; 2020 Jun; 41(23):2168-2179. PubMed ID: 31834357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuropeptide-Y causes coronary microvascular constriction and is associated with reduced ejection fraction following ST-elevation myocardial infarction.
    Herring N; Tapoulal N; Kalla M; Ye X; Borysova L; Lee R; Dall'Armellina E; Stanley C; Ascione R; Lu CJ; Banning AP; Choudhury RP; Neubauer S; Dora K; Kharbanda RK; Channon KM;
    Eur Heart J; 2019 Jun; 40(24):1920-1929. PubMed ID: 30859228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relation of plasma neuropeptide-Y with myocardial function and infarct severity in acute ST-elevation myocardial infarction.
    Tiller C; Reindl M; Holzknecht M; Lechner I; Troger F; Oberhollenzer F; von der Emde S; Kremser T; Mayr A; Bauer A; Metzler B; Reinstadler SJ
    Eur J Intern Med; 2024 Aug; 126():63-68. PubMed ID: 38555253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuropeptide-Y Levels in ST-Segment-Elevation Myocardial Infarction: Relationship With Coronary Microvascular Function, Heart Failure, and Mortality.
    Gibbs T; Tapoulal N; Shanmuganathan M; Burrage MK; Borlotti A; Banning AP; Choudhury RP; Neubauer S; Kharbanda RK; Ferreira VM; Channon KM; Herring N;
    J Am Heart Assoc; 2022 Jul; 11(13):e024850. PubMed ID: 35766271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peripheral cardiac sympathetic hyperactivity in cardiovascular disease: role of neuropeptides.
    Shanks J; Herring N
    Am J Physiol Regul Integr Comp Physiol; 2013 Dec; 305(12):R1411-20. PubMed ID: 24005254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship of plasma neuropeptide Y with angiographic, electrocardiographic and coronary physiology indices of reperfusion during ST elevation myocardial infarction.
    Cuculi F; Herring N; De Caterina AR; Banning AP; Prendergast BD; Forfar JC; Choudhury RP; Channon KM; Kharbanda RK
    Heart; 2013 Aug; 99(16):1198-203. PubMed ID: 23403409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac sympathetic activation circumvents high-dose beta blocker therapy in part through release of neuropeptide Y.
    Hoang JD; Salavatian S; Yamaguchi N; Swid MA; David H; Vaseghi M
    JCI Insight; 2020 Jun; 5(11):. PubMed ID: 32493842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk assessment model for predicting ventricular tachycardia or ventricular fibrillation in ST-segment elevation myocardial infarction patients who received primary percutaneous coronary intervention.
    Huang J; Peng X; Fang Z; Hu X; Zhou S
    Medicine (Baltimore); 2019 Jan; 98(4):e14174. PubMed ID: 30681585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperuricemia is associated with an increased prevalence of ventricular tachycardia and fibrillation in patients with ST-elevation myocardial infarction after primary percutaneous coronary intervention.
    Hu X; Fu S; Wang S
    BMC Cardiovasc Disord; 2022 Apr; 22(1):199. PubMed ID: 35473480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cardiac sympathetic co-transmitter galanin reduces acetylcholine release and vagal bradycardia: implications for neural control of cardiac excitability.
    Herring N; Cranley J; Lokale MN; Li D; Shanks J; Alston EN; Girard BM; Carter E; Parsons RL; Habecker BA; Paterson DJ
    J Mol Cell Cardiol; 2012 Mar; 52(3):667-76. PubMed ID: 22172449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of sympathetic vasoconstriction in pigs in vivo by the neuropeptide Y-Y1 receptor antagonist BIBP 3226.
    Lundberg JM; Modin A
    Br J Pharmacol; 1995 Dec; 116(7):2971-82. PubMed ID: 8680732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early Ventricular Tachycardia or Fibrillation in Patients With ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention and Impact on Mortality and Stent Thrombosis (from the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction Trial).
    Kosmidou I; Embacher M; McAndrew T; Dizon JM; Mehran R; Ben-Yehuda O; Mintz GS; Stone GW
    Am J Cardiol; 2017 Nov; 120(10):1755-1760. PubMed ID: 28867126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Electrocardiographic parameters effectively predict ventricular tachycardia/fibrillation in acute phase and abnormal cardiac function in chronic phase of ST-segment elevation myocardial infarction.
    Yu Z; Chen Z; Wu Y; Chen R; Li M; Chen X; Qin S; Liang Y; Su Y; Ge J
    J Cardiovasc Electrophysiol; 2018 May; 29(5):756-766. PubMed ID: 29399929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuropeptide Y facilitates P2X1 receptor-dependent vasoconstriction via Y1 receptor activation in small mesenteric arteries during sympathetic neurogenic responses.
    Gonzalez-Montelongo MDC; Fountain SJ
    Vascul Pharmacol; 2021 Feb; 136():106810. PubMed ID: 33181321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Life-threatening arrhythmias in anterior ST-segment elevation myocardial infarction patients treated by percutaneous coronary intervention: adverse impact of morphine.
    Sauer F; Jesel L; Marchandot B; Derimay F; Bochaton T; Amaz C; Roubille F; Cayla G; Rioufol G; Garcia-Dorado D; Claeys M; Angoulvant D; Bonnefoy-Cudraz E; Guérin P; Trinh A; Matsushita K; Ohlmann P; Jossan C; Mewton N; Ovize M; Morel O
    Eur Heart J Acute Cardiovasc Care; 2021 May; 10(4):427-436. PubMed ID: 33620376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuropeptide Y (NPY) and the pig heart: release and coronary vasoconstrictor effects.
    Rudehill A; Sollevi A; Franco-Cereceda A; Lundberg JM
    Peptides; 1986; 7(5):821-6. PubMed ID: 3025824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterogeneity of prejunctional NPY receptor-mediated inhibition of cardiac neurotransmission.
    Serone AP; Wright CE; Angus JA
    Br J Pharmacol; 1999 May; 127(1):99-108. PubMed ID: 10369461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early repolarization pattern on ECG recorded before the acute coronary event does not predict ventricular fibrillation during ST-elevation myocardial infarction.
    Demidova MM; Carlson J; Erlinge D; Platonov PG
    Heart Rhythm; 2020 Apr; 17(4):629-636. PubMed ID: 31734288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relation between myocardial infarct size and ventricular tachyarrhythmia among patients with preserved left ventricular ejection fraction following fibrinolytic therapy for ST-segment elevation myocardial infarction.
    Pride YB; Appelbaum E; Lord EE; Sloan S; Cannon CP; Sabatine MS; Gibson CM;
    Am J Cardiol; 2009 Aug; 104(4):475-9. PubMed ID: 19660597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuropeptide Y release in the rat spinal cord measured with Y1 receptor internalization is increased after nerve injury.
    Marvizon JC; Chen W; Fu W; Taylor BK
    Neuropharmacology; 2019 Nov; 158():107732. PubMed ID: 31377198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.